<DOC>
	<DOCNO>NCT02549677</DOCNO>
	<brief_summary>The purpose study compare safety efficacy epirubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide lymph node positive , estrogen receptor ( ER ) positive , human epithelial growth factor receptor 2 ( HER2 ) negative breast cancer patient adjuvant chemotherapy .</brief_summary>
	<brief_title>Epirubicin Versus Docetaxel Plus Cyclophosphamide Lymph Node Negative , ER-positive , Her2-negative Breast Cancer</brief_title>
	<detailed_description>This non-inferiority study . According previous study result , investigator hypothesize incidence grade 3-4 neutropenia 40 % , α 0.05 β 0.8 , sample size 264 case need .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Women age ≥18 year &lt; 70 year life expectancy &gt; 12 month 2 . Have finish radical operation , pathologically verify lymph node involvement 3 . Operation specimens available ER , progesterone receptor ( PR ) Her2 detection , patient ER positive , Her2 negative tumor . 4 . Adequate bone marrow function 5 . Adequate liver renal function 6 . Has Eastern Cooperative Oncology Group ( ECOG0 Performance Score 01 ; 7 . Women potential childbearing must negative pregnancy test ( urine serum ) within 7 day drug administration agree use acceptable method birth control avoid pregnancy duration study ; 8 . Written inform consent accord local ethic committee requirement . 1 . Prior systemic locoregional treatment breast cancer , include chemotherapy ; 2 . Metastatic breast cancer ; 3 . With history malignant tumor except uterine cervix cancer situ skin basal cell carcinoma ; 4 . Patients medical condition indicate intolerant adjuvant chemotherapy relate treatment , include uncontrolled pulmonary disease , diabetes mellitus , severe infection , active peptic ulcer , coagulation disorder , connective tissue disease myelosuppressive disease ; 5 . Has active hepatitis B hepatitis C abnormal liver function test ( LFTs ) know HIV positive ; 6 . History congestive heart failure , uncontrolled symptomatic angina pectoris , arrhythmia myocardial infarction ; poorly control hypertension ; 7 . Has peripheral neuropathy ≥ grade 1 ; 8 . Patient pregnant breast feeding ; 9 . Known severe hypersensitivity drug study ; 10 . Treatment investigational drug within 30 day begin study treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>